POINT Biopharma Global (PNT) 10-K 25 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 21, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-39311
Entity Registrant Name	POINT BIOPHARMA GLOBAL INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-0800493
Entity Address, Address Line One	4850 West 78th Street
Entity Address, City or Town	Indianapolis
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46268
City Area Code	647
Local Phone Number	812-2417
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	PNT
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 654.6
Entity Common Stock, Shares Outstanding		90,122,472
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Information required in response to Part III of Form 10-K (Item 14) is hereby incorporated by reference to portions of the Registrant’s Proxy Statement for the Annual Meeting of Stockholders to be held in 2022. The Proxy Statement will be filed by the Registrant with the Securities and Exchange Commission no later than 120 days after the end of the Registrant’s fiscal year ended December 31, 2021.
Entity Central Index Key	0001811764
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Audit Information [Abstract]
Auditor Name	Armanino LLP
Auditor Location	San Jose, California
Auditor Firm ID	32

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 238,815,991	$ 10,546,749
Prepaid expenses and other current assets	5,030,565	1,850,346
Total current assets	243,846,556	12,397,095
Property, plant and equipment	19,412,086	9,797,400
Total assets	263,258,642	22,194,495
Current liabilities
Accounts payable	1,738,470	3,596,634
Accrued liabilities	5,990,516	1,479,041
Income taxes payable	250,978	87,882
Total current liabilities	7,979,964	5,163,557
Deferred tax liability	65,592	0
Mortgage payable, net of debt discount	0	3,550,660
Total liabilities	8,045,556	8,714,217
Commitments and contingencies (Note 12)
Stockholders' equity
Common Stock, par value $0.0001 per share, 430,000,000 authorized, 90,121,794 and 54,647,656 issued and outstanding as of December 31, 2021 and December 31, 2020, respectively	9,012	5,465
Additional paid-in capital	314,488,782	26,857,040
Accumulated deficit	(59,284,708)	(13,382,227)
Total stockholders' equity	255,213,086	13,480,278
Total liabilities and stockholders' equity	$ 263,258,642	$ 22,194,495

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.001	$ 0.0001
Common stock, authorized (in shares)	430,000,000		430,000,000
Common stock, shares issued (in shares)	90,121,794		54,647,656
Common stock, shares outstanding (in shares)	90,121,794		54,647,656

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses
Research and development	$ 33,505,392	$ 9,142,156
General and administrative	12,006,438	3,972,649
Total operating expenses	45,511,830	13,114,805
Loss from operations	(45,511,830)	(13,114,805)
Other expenses
Finance costs	(11,840)	(5,354)
Foreign currency loss	(73,153)	(164,962)
Total other expenses	(84,993)	(170,316)
Loss before provision for income taxes	(45,596,823)	(13,285,121)
Provision for income taxes	(305,658)	(87,882)
Net loss	$ (45,902,481)	$ (13,373,003)
Net loss per basic and diluted common share:
Basic net loss per common share (in dollars per share)	$ (0.62)	$ (0.34)
Diluted net loss per common share (in dollars per share)	$ (0.62)	$ (0.34)
Basic weighted average common shares outstanding (in shares)	73,850,822	38,875,643
Diluted weighted average common shares outstanding (in shares)	73,850,822	38,875,643

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2019		0
Beginning balance at Dec. 31, 2019	$ (9,224)	$ 0	$ 0	$ (9,224)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock net of issuance costs of $324,555 (in shares)		54,647,656
Issuance of shares of Common Stock net of issuance costs of $324,555	22,575,379	$ 5,465	22,569,914	0
Issuance of warrants	2,526,320		2,526,320
Stock-based compensation	1,760,806		1,760,806
Net loss	$ (13,373,003)			(13,373,003)
Ending balance (in shares) at Dec. 31, 2020	54,647,656	54,647,656
Ending balance at Dec. 31, 2020	$ 13,480,278	$ 5,465	26,857,040	(13,382,227)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock net of issuance costs of $324,555 (in shares)		800,000
Issuance of shares of Common Stock in connection with exercise of warrants (in shares)		2,869,799
Issuance of shares of Common Stock in connection with exercise of warrants	20,000,000	$ 287	19,999,713
Issuance of shares of Common Stock in connection with stock option exercises (in shares)		64,570
Issuance of shares of Common Stock in connection with stock option exercises	450,000	$ 6	449,994
Issuance of shares of Common Stock, net of direct and incremental costs in connection with the Business Combination (refer to Note 3) (in shares)		32,539,769
Issuance of shares of Common Stock, net of direct and incremental costs in connection with the Business Combination (refer to Note 3)	264,882,682	$ 3,254	264,879,428
Stock-based compensation	2,302,607		2,302,607
Net loss	$ (45,902,481)			(45,902,481)
Ending balance (in shares) at Dec. 31, 2021	90,121,794	90,121,794
Ending balance at Dec. 31, 2021	$ 255,213,086	$ 9,012	$ 314,488,782	$ (59,284,708)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Deficit) (Parentheticals)	12 Months Ended
	Dec. 31, 2020USD ($)
Statement of Stockholders' Equity [Abstract]
Cost and fees on issuance of common shares	$ 324,555

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss:	$ (45,902,481)	$ (13,373,003)
Adjustments to reconcile net loss to net cash used in operating activities:
Deferred income taxes	65,592	0
Share-based compensation expense	2,302,607	1,760,806
Amortization of debt issuance costs	11,840	5,354
Changes in operating assets and liabilities
Prepaid expenses and other current assets	(3,180,219)	(1,849,170)
Accounts payable	(2,022,472)	3,596,634
Accrued liabilities	3,790,310	1,479,041
Income taxes payable	163,096	87,882
Amount due to related party within accrued liabilities	72,969	(10,400)
Net cash used in operating activities	(44,698,758)	(8,302,856)
Cash flows from investing activities
Purchase of property, plant and equipment	(8,802,182)	(9,797,400)
Net cash used in investing activities	(8,802,182)	(9,797,400)
Cash flows from financing activities
Issuance of shares of Common Stock in connection with exercise of warrants	20,000,000
Issuance of shares of Common Stock in connection with stock option exercises	450,000
Issuance of shares of Common Stock in connection with the Business Combination (see Note 3), net of direct and incremental costs paid	264,882,682
Repayment of mortgage payable	(3,562,500)	0
Costs and fees on issuance of Common Stock		(324,555)
Borrowings on mortgage payable, net of debt discount		3,545,306
Issuance of Common Stock and warrants to purchase Common Stock of POINT Biopharma Inc.		25,426,254
Net cash provided by financing activities	281,770,182	28,647,005
Net increase in cash and cash equivalents	228,269,242	10,546,749
Cash and cash equivalents, beginning of period	10,546,749	0
Cash and cash equivalents, end of period	238,815,991	10,546,749
Supplemental disclosure of cash flow information:
Cash paid for income taxes	(68,785)	0
Cash paid for interest on mortgage payable	(92,338)	(25,462)
Non-cash investment activities:
Purchase of property, plant and equipment recorded in accounts payable and accrued liabilities	$ 812,504	$ 0

Nature of business

Nature of business	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of business	Nature of business Formation and organization POINT Biopharma Global Inc., together with its consolidated subsidiaries (the “Company”), is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. On September 18, 2019, POINT Theranostics Inc. was incorporated under the General Corporation Law of the State of Delaware (the "DGCL") and amended its name to “POINT Biopharma Inc.” on November 22, 2019. On June 30, 2021, following the Business Combination (as defined below), POINT Biopharma Inc. became a wholly-owned subsidiary of POINT Biopharma Global Inc. Under the terms of the Business Combination Agreement (as defined below), stockholders of POINT Biopharma Inc. received approximately 3.59 shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”) in exchange for each common share of Point Biopharma Inc. Also in connection with the closing of the Business Combination, RACA (as defined below) consummated the sale of an aggregate of 16,500,000 shares of Class A common stock, par value $0.0001 per share, of RACA (“Class A Common Stock”) in a private placement at a price of $10.00 per share, for aggregate gross proceeds of $165,000,000 (“PIPE Financing”). In accordance with the terms of the Business Combination Agreement, upon the closing of the Business Combination (as defined below), each share of Class A Common Stock and each share of Class B common stock, par value $0.0001 per share, of RACA (“Class B Common Stock”) was converted into one share of Common Stock of the Company. For additional information on the Business Combination, please see Note 3. The Company was founded on a mission to make radioligand therapy applicable to more cancers and available to more people, thereby improving the lives of cancer patients and their families everywhere. The Company has four wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma USA Inc. and West 78th Street, LLC, each located in the USA, and POINT Biopharma Corp., located in Canada. The Company’s headquarters is located at 4850 West 78th Street, Indianapolis, Indiana, 46268.

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Basis of presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma Corp., POINT Biopharma USA, Inc. and West 78th Street, LLC, for financial information and pursuant to the rules and regulations of the SEC. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and accompanying notes have been prepared in accordance with the provisions of ASC Topic 205-40, Presentation of Financial Statements—Going Concern on the basis that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities an commitments in the normal course of business. Impact of Covid-19 and other geopolitical events The COVID-19 pandemic, which was declared by the World Health Organization as a pandemic in March 2020 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border security and other measures. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society, which has resulted, and will likely continue to result, in significant disruptions to the global economy as well as businesses and capital markets around the world. The future progression of the pandemic and its effects on the Company’s business and operations are uncertain. In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company has taken precautionary measures, including implementing work-from-home policies for certain employees. The impact of the virus, including work-from-home policies, may negatively impact productivity, disrupt the Company’s business, and delay its preclinical research and clinical trial activities and its development program timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct its business in the ordinary course. Specifically, the Company may not be able to enroll additional patient cohorts on its planned timeline due to disruptions at its clinical trial sites. The Company is currently unable to predict when it will be able to resume normal clinical activities for its clinical programs. Other impacts to the Company’s business may include temporary closures of its suppliers and disruptions or restrictions on its employees’ ability to travel. Any prolonged material disruption to the Company’s employees or suppliers could adversely impact the Company’s preclinical research and clinical trial activities, financial condition and results of operations, including its ability to obtain financing. Additionally, financial markets may be adversely affected by the current or anticipated impact of military conflict, including escalating military fighting between Russia and Ukraine, terrorism or other geopolitical events. The U.S. and other nations in response to the Russo-Ukrainian conflict have announced economic sanctions which may have an adverse effect on the global financial markets, which, in turn, could have an adverse effect on our business, financial condition and results of operations. The Company's SPLASH trial has vendor staff in Ukraine, and any political instability in the region may disrupt resourcing assigned to the trial and negatively impact or business. The Company is monitoring the potential impact of the COVID-19 pandemic and the Russo-Ukrainian conflict on its business and consolidated financial statements. To date, the Company has not experienced any material business disruptions or incurred any impairment losses in the carrying values of its assets as a result of these events and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these consolidated financial statements. Risks and uncertainties The Company has incurred significant net losses since inception and, prior to the Business Combination, has funded operations through equity financings. Operating losses and negative cash flows are expected to continue for the foreseeable future. As losses continue to be incurred, the Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of the COVID-19 coronavirus, the impact of the Russo-Ukrainian conflict, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuations of stock options and warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Foreign currency and currency translation The reporting currency of the Company is the U.S. dollar. The functional currency of the Company’s legal entities including its parent is also the U.S. dollar. As a result, the Company records no cumulative translation adjustments related to translation of unrealized foreign exchange gains or losses. Realized foreign exchange gains and losses that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income (expense), net in the consolidated statements of operations, as incurred. Account balances denominated in a currency other than the local currency are translated at the year-end spot rate with the unrealized exchanged gains and losses included in other income (expense) net in the consolidated statements of operations. Fair value of financial instruments Cash and cash equivalents are carried at fair value. Other financial instruments, including accounts payable and mortgage payable, are carried at amortized cost, which approximates fair value given their short-term nature. Fair value measurements Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1 — Quoted prices in active markets for identical assets or liabilities. Cash and cash equivalents fall within level 1 of the fair value hierarchy. • Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Cash and cash equivalents The Company considers all highly liquid instruments with an original maturity of three months or less as cash equivalents. Property in development Property in development includes the purchase price of the land and building for the Company’s manufacturing facility in Indianapolis, Indiana, plus other acquisition-related costs. The Company also capitalizes all direct costs relating to the development of this property including interest on its mortgage borrowings and direct development costs identified with the property. Once the asset is complete and available for use, the costs of construction are transferred to the appropriate category of property, plant and equipment, and depreciation commences. Leases Currently, the Company only holds short term leases and has elected to apply the short-term lease exemption. For all future lease arrangements, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement and in accordance with the guidance of ASC 842. Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. The Company currently does not have financing leases. The Company has elected not to recognize leases with an original term of one year or less on the consolidated balance sheets. Options to renew or early terminate a lease are included in the initial lease term of a lease when there is reasonable certainty that the option will be applied. The Company’s lease expense is recognized in the consolidated statements of operations according to its use in either research and development expenses or general administrative expenses. Currently, all lease expense is recorded in general and administrative expense. Warrants Common share purchase warrants entitle the holder to acquire common shares of the Company at a specified price for a specified period of time, which are classified as equity. Warrants are measured at the date of issuance using the Black-Scholes-Merton option pricing model. On January 28, 2021, all outstanding warrants to purchase common shares of the Company were exercised resulting in cash proceeds of $20,000,000. Research and development costs Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including costs for salaries and bonuses, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, share-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered. Upfront payments under license agreements are expensed as research and development expense upon receipt of the license, and annual maintenance fees under license agreements are expensed in the period in which they are incurred. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable. Acquired in-process research and development costs The Company has entered into various research, development and manufacturing contracts with research institutions and other companies. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. The upfront payments to acquire a new drug compound, as well as subsequent milestone payments, are immediately expensed as acquired in-process research and development, provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use. Once regulatory approval is received, payments to acquire rights, and the related milestone payments, are capitalized and the amortization of such assets recorded to product cost of sales. Share-based compensation expense The Company recognizes share-based compensation expense for all share-based awards made to employees, directors and consultants based on estimated fair values. The Company determines share-based compensation on the grant date using the Black-Scholes-Merton option pricing model. The value of the award is recognized as expense on a straight-line basis over the requisite service period. ASC 718 - Stock Compensation ("ASC 718") allows for forfeitures to be recognized in the period in which they occur. ASC 718 aligns the accounting for share-based payments to non-employees with that of employees, with certain exceptions. Income taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company may be entitled to investment tax credits in connection with its research and development costs. These investment tax credits are non-refundable tax credits and are accounting for in accordance with the Company’s income tax accounting policies. Net income (loss) per share Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding warrants and stock options are considered potential dilutive common shares. Segment information The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company’s focus is on the development of radioligand therapy for the treatment of cancer. Recent accounting pronouncements not yet effective Debt with Conversion and Other Options The FASB has issued ASU 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible instruments, such as convertible debt or convertible preferred stock, by eliminating two potential methods in accounting for the embedded conversion feature. The standard also removes certain conditions previously used to evaluate whether a freestanding financial instrument, or certain types of embedded features, are considered to be settled in the issuer’s own equity. Finally, ASU 2020-06 requires that an entity use the if-converted method in calculating the effects of convertible instruments on diluted earnings per share, with one limited exception. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than for fiscal years beginning after December 15, 2020. The Company is currently evaluating the effects of this guidance. Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options The FASB has issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) . ASU 2021-04 provides guidance that an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. The standard also provides guidance on how an entity should measure and recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2021. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently evaluating the effects of this guidance. Government Assistance The FASB has issued ASU 2021-10, Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance . ASU 2021-10 provides guidance to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2021. Early application of the amendments is permitted. The Company is currently evaluating the effects of this guidance.

Business Combination

Business Combination	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Business Combination	Business Combination On March 15, 2021, POINT Biopharma Inc. entered into a definitive business combination agreement (the “Business Combination Agreement”) with Therapeutics Acquisition Corp. (NASDAQ:RACA), d/b/a Research Alliance Corp. I (“RACA”), a special purpose acquisition company sponsored by RA Capital Management L.P., that was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. On June 30, 2021, (the “Closing Date”), Bodhi Merger Sub, Inc., a wholly-owned subsidiary of RACA, merged with and into POINT Biopharma Inc. (the “Business Combination”), with POINT Biopharma Inc. as the surviving company in the Business Combination and, after giving effect to such Business Combination, POINT Biopharma Inc. became a wholly-owned subsidiary of RACA. RACA was then renamed “POINT Biopharma Global Inc.” In accordance with the terms of the Business Combination Agreement, upon the closing of the Business Combination: (i) each share and vested equity award of POINT Biopharma Inc. outstanding as of immediately prior to the Closing Date was converted into shares of Common Stock of the Company or comparable vested equity awards that are exercisable for shares of Common Stock of the Company, based on an implied vested equity value of $585,000,000 (which is equal to a conversion ratio of approximately 3.59-for-1); (ii) all unvested equity awards of POINT Biopharma Inc. were converted into comparable equity awards that are exercisable for shares of Common Stock of the Company, determined based on the same conversion ratio at which the vested equity awards are converted into shares of Common Stock of the Company; and (iii) each share of RACA Class A Common Stock and each share of RACA Class B Common Stock that was issued and outstanding immediately prior to the Closing Date became one share of Common Stock of the Company. In connection with the Business Combination, the Company consummated the PIPE Financing, pursuant to which it received $165.0 million in exchange for 16,500,000 shares of Common Stock of the Company. After giving effect to the Business Combination, there were 90,121,794 shares of Common Stock issued and outstanding. We accounted for the Business Combination as a reverse recapitalization, in accordance with U.S. GAAP. POINT Biopharma Inc. is treated as the accounting acquirer (legal acquiree), while RACA is the accounting acquiree (legal acquirer) for financial reporting purposes. This determination is primarily based on the fact that the former POINT Biopharma Inc. stockholders retained a majority of the voting power of the Company and comprise a majority of the governing body of the Company, and the former POINT Biopharma Inc. senior management comprise substantially all of the senior management of the Company. Accordingly, for accounting purposes, the Business Combination is treated as the equivalent of POINT Biopharma Inc. issuing shares for the net assets of RACA, accompanied by a recapitalization. The net assets of RACA are stated at historical costs. No goodwill or other intangible assets is recorded. In connection with the Business Combination, the Company incurred underwriting fees and other costs considered to be direct or incremental to the proceeds raised in connection with the Business Combination and PIPE Financing totaling approximately $21.9 million, consisting of costs incurred by RACA prior to the completion of the Business Combination as well as investment banker, legal, audit, tax, accounting and listing fees. These amounts are reflected within additional paid-in capital in the consolidated balance sheet as of December 31, 2021. Summary of net proceeds The following table summarizes the elements of the net proceeds from the Business Combination: Recapitalization Cash - RACA Trust and cash (net of redemptions) $ 121,770,367 Cash - PIPE Financing 165,000,000 Less: Underwriting fees, costs incurred by RACA and other direct and incremental costs, each paid prior to December 31, 2021 (21,887,685) Net proceeds from the Business Combination, net of costs incurred by RACA and direct and incremental costs paid per the statement of cash flows $ 264,882,682 The net proceeds noted above exclude approximately $4.7 million in transaction costs that were not considered direct and incremental to the raising of capital. These costs consist of corporate expenses in the normal course of business comprised of accounting, consulting, insurance and board retainer fees. These costs were recorded as incurred in accordance with the nature of the services received. Summary of shares of Common Stock issued The following table summarizes the number of shares of Common Stock outstanding immediately following the consummation of the Business Combination: Number of RACA Class A and Class B shares outstanding prior to the Business Combination 16,039,769 Class A shares issued pursuant to the PIPE Financing 16,500,000 Common Stock issued upon conversion of RACA Class A Common Stock and Class B Common Stock and PIPE Financing shares 32,539,769 Common Stock issued upon conversion of POINT Biopharma Inc. common shares 57,582,025 Total shares of Common Stock outstanding immediately following the Business Combination 90,121,794

Cash and cash equivalents

Cash and cash equivalents	12 Months Ended
	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	Cash and cash equivalentsAs at December 31, 2021, the Company’s cash and cash equivalents balance was $238.8 million (December 31, 2020 — $10.5 million). The Company’s cash and cash equivalents balance represents cash deposited with financial institutions.

Prepaid expenses and other curr

Prepaid expenses and other current assets	12 Months Ended
	Dec. 31, 2021
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses and other current assets	Prepaid expenses and other current assetsPrepaid expenses and other current assets consisted of the following: As at December 31, As at December 31, $ $ Insurance 2,175,379 — Prepaid clinical trial expenses 1,973,609 1,763,731 Deposit on production equipment 703,461 — Canadian harmonized sales tax receivable 72,666 58,982 Other 105,450 27,633 Total 5,030,565 1,850,346

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Property, plant and equipment Property, plant and equipment consisted of the following: As at December 31, As at December 31, $ $ Property in development 16,561,032 9,797,400 Machinery and equipment 2,132,768 — Furniture and fixtures 590,545 — Computer equipment 127,741 — Total 19,412,086 9,797,400 On July 2020, the Company purchased land and a building in Indianapolis, Indiana (which has been expanded to approximately 81,000 square feet) for the purpose of retrofitting the existing building into a state-of-the-art, Good Manufacturing Practices ("GMP") compliant facility that will expand the Company’s drug manufacturing operations. The purchase of the property was financed by a mortgage that was repaid on July 29, 2021 (see Note 9). The Company commenced the manufacture of clinical supply in the Indianapolis manufacturing facility in January 2022. The Company has determined this to be the date upon which its property, plant and equipment was ready for its intended use and the date upon which to commence depreciating the assets.

Accounts payable

Accounts payable	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Accounts payable	Accounts payable Accounts payable consisted of the following: As at December 31, As at December 31, $ $ Accounts payable 1,730,304 3,595,745 Other payables 8,166 889 Total 1,738,470 3,596,634

Accrued expenses

Accrued expenses	12 Months Ended
	Dec. 31, 2021
Accrued Liabilities, Current [Abstract]
Accrued expenses	Accrued expensesAccrued liabilities consisted of the following: As at December 31, As at December 31, $ $ Accrued personnel costs 3,440,558 540,292 Accrued research and development costs 1,142,056 597,994 Accrued costs for the purchases of property, plant and equipment 648,196 — Accrued corporate legal fees and other professional services 654,945 210,099 Other accrued costs 104,761 130,656 Total 5,990,516 1,479,041

Mortgage payable

Mortgage payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Mortgage payable	Mortgage payable On July 10, 2020, the Company obtained a mortgage loan in the amount of $3,562,500 (the “Mortgage”) for the purpose of purchasing land and a building located in Indianapolis, Indiana (the “Property”) (see Note 6). The Mortgage was collateralized by a first charge over the Property. As part of the financing, the Company incurred $17,194 of costs and fees from the lender that were capitalized and recorded as finance costs over the life of the Mortgage. On July 29, 2021, the Mortgage on the manufacturing facility in Indianapolis, Indiana was repaid and the related mortgage on the Company's facility in Indianapolis, Indiana was released. Prior to its repayment, the Mortgage bore interest at 2.85% plus a minimum rate of 1-month LIBOR, subject to a LIBOR floor of 0.25%. The Mortgage required quarterly interest payments, which commenced on October 1, 2020, with the principal amount due at maturity on January 10, 2022. For the year ended December 31, 2021, the Company recorded $63,195 in interest costs (December 31, 2020 - $54,605) which have been capitalized within property, in development, and $11,840 in amortization of debt issuance costs (December 31, 2020 - $5,354) through finance costs.

Stockholders_ equity

Stockholders’ equity	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Stockholders’ equity	Stockholders’ equity Common and Preferred Stock The Company is authorized to issue 430,000,000 shares of Common Stock, as well as 20,000,000 of shares of preferred stock, with a par value of $0.0001 per share (“Preferred Stock”). The figures below are presented giving effect to a retroactive application of the Business Combination which resulted in a conversion of the previous POINT Biopharma Inc. common shares to shares of Common Stock of the Company at a conversion ratio of approximately 3.59:1. The par value of previous POINT Biopharma Inc. common shares was $0.001. See Note 3 for additional details. During the year ended December 31, 2021, the Company (a) issued 32,539,769 shares of Common Stock in connection with the Business Combination and PIPE Financing (see Note 3) and (b) issued 800,000 shares of common stock of POINT Biopharma Inc. (exchanged for 2,869,799 shares of Common Stock) in connection with the exercise of warrants and 18,000 shares of common stock of POINT Biop harma Inc. (exchanged for 64,570 shares of Common Stock) in connection with the exercise of stock options issued to a non-employee consultant, resulting in total cash proceeds of $20,450,000. During the year ended December 31, 2020, the Company (a) issued 13,375,384 of shares of common stock of POINT Biopharma Inc. (exchanged for 47,980,765 shares of Common Stock) at $0.01 per share raising $133,754, (b) issued 1,058,500 shares of common stock of POINT Biopharma Inc. (exchanged for 3,797,096 shares of Common Stock) at $5.00 per share, raising $5,292,500, and (c) issued 800,000 of shares of common stock of POINT Biopharma Inc. (exchanged for 2,869,795 Common Stock) at $25 per share, raising $20,000,000, as part of the Series A private placement financing. In connection with the Series A private placement financing, the Compan y incurred costs and fees totaling $324,555 which have been recorded against the proceeds of the issuance. As of December 31, 2021, the number of total issued and outstanding shares of Common Stock was 90,121,794 (December 31, 2020 – 54,647,656). Each share of Common Stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, if any, as may be declared by the Company’s board of directors. During the year ended December 31, 2021, no cash dividends had been declared or paid by the Company (December 31, 2020 — $nil). The Company’s board of directors has the authority to issue shares of Preferred Stock from time to time on terms it may determine, to divide shares of Preferred Stock into one or more series and to fix the designations, preferences, privileges, and restrictions of Preferred Stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the DGCL. During the year ended December 31, 2021, no shares of Preferred Stock have been issued by the Company (December 31, 2020 — nil). Warrants During the year ended December 31, 2020, in connection with the Series A private placement financing, the Company issued warrants to purchase an aggregate of 800,000 shares of common stock of POINT Biopharma Inc. to an institutional investor at an exercise price of $25.00 per share. The warrants were issued for no additional consideration, and the specified exercise prices of each warrant are subject to adjustment for share dividends, share splits, combination or other similar recapitalization transactions as provided under the terms of the warrants. The warrants were set to expire July 29, 2021. On January 28, 2021, the holder exercised the warrants and acquired 800,000 shares of common s tock of POINT Biopharma Inc. (exchanged for 2,869,799 shares of Common Stock) and the Company received cash proceeds of $20,000,000. The Company valued the warrants using the Black-Scholes-Merton option pricing model with the following inputs: Year ended December 31, 2020 Risk-free interest rate 0.13 % Expected term (in years) 1 Expected volatility 65 % Expected dividend yield 0 % The allocation of the total proceeds between the common shares issued and the warrants was performed using the relative fair value method resulting in the recording of $2,526,320 to warrants within stockholders’ equity within the year ended December 31, 2020.

Share-based compensation

Share-based compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Share-based compensation	Share-based compensation Equity Incentive Plans In March 2020, the board of directors of POINT Biopharma Inc. approved the 2020 Equity Incentive Plan (the “2020 EIP”). The 2020 EIP provided for the granting of incentive and non-qualified stock options, stock appreciation rights, restricted stock units, performance awards and other stock-based awards to employees, directors, and consultants of POINT Biopharma Inc. Effective as of June 30, 2021, in connection with the Business Combination, the Company’s board of directors adopted the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (the “2021 EIP”) to replace the 2020 EIP and allow the Company to grant equity and equity-based incentive awards to officers, employees, non-employee directors and consultants of the Company. Upon the closing of the Business Combination, the Company assumed the outstanding equity awards under the 2020 EIP and each outstanding option to acquire common shares of POINT Biopharma Inc. (whether vested or unvested) under the 2020 EIP was substituted with a substantially equivalent option to acquire shares of Common Stock of the Company based on the conversion ratio for the POINT Biopharma Inc. common shares in the Business Combination and remains outstanding under the 2020 EIP. No further grants may be made under the 2020 EIP. As of December 31, 2021 there were 7,438,527 shares of Common Stock authorized for issuance under the 2021 EIP. The 2021 EIP provides that the number of shares reserved and available for issuance under the 2021 EIP will automatically increase each January 1, beginning on January 1, 2022, by 4% of the outstanding number of common shares on the immediately preceding December 31, or such lesser amount as determined by the Board. As of January 1, 2022, the number of shares of Common Stock available under the 2021 EIP increased by 3,604,871. The Company concluded that the replacement stock options issued in connection with the Business Combination did not require accounting for effects of the modification under the ASC 718 – Compensation – Stock Compensation (“ASC 718”) as it was concluded that (a) the fair value of the modified award is the same as the fair value of the original award immediately before the original award was modified, (b) there are no changes to the vesting conditions of the award, and (c) there is no change to the classification of the award. Stock options generally vest over a four-year period, with 25% vesting after the 1st year anniversary and the remaining options vesting ratably over the remaining three years. All employee stock options generally expire 6 years from the date of the grant. The Company also issued certain stock opt ions to non-employee service providers during the year ended December 31, 2021. Share-based compensation expense for the years ended December 31, 2021 and 2020 was recognized in the Consolidated Statements of Operations as follows: Year ended December 31, 2021 Year ended December 31, 2020 $ $ Research and development 1,899,471 398,139 General and administrative 403,136 1,362,667 Total share-based compensation expense 2,302,607 1,760,806 The Company did not recognize a tax benefit related to share-based compensation expense during the years ended December 31, 2021 and December 31, 2020 as the Company had net operating losses carryforwards and recorded a valuation allowance against the deferred tax asset. Stock option valuation and activity The fair value of stock option grants is estimated using the Black-Scholes-Merton option-pricing model. The Company lacks sufficient company-specific historical and implied volatility information. Therefore, it estimates its expected share volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The following table presents the assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted: Year ended December 31, 2021 Year ended December 31, 2020 Risk-free interest rate 0.66% – 1.16% 0.11% – 0.50% Expected term (in years) 4.25 – 5.38 0.35 – 4.25 Expected volatility 65% – 73% 65% Expected dividend yield 0% 0% The following table summarizes the activity relating to the Company’s options to purchase stock. The below stock option figures are presented giving effect to a retroactive application of the Business Combination which resulted in a replacement of the previous POINT Biopharma Inc. stock options with stock options of the Company, as described above, at a conversion ratio of approximately 3.59:1. In addition, the exercise price for each replacement stock option is also adjusted using the ratio of approximately 3.59:1. See Note 3 for additional details: Number of Weighted Weighted- Aggregate Outstanding as of December 31, 2020 2,364,010 2.88 Granted 1,614,683 7.81 Exercised (64,570) 6.97 Forfeited (88,372) 7.80 Outstanding as of December 31, 2021 3,825,751 4.78 5.2 7,302,047 Vested and expected to vest as of December 31, 2021 3,825,751 4.78 5.2 7,302,047 Options exercisable as of December 31, 2021 1,018,775 4.60 6.0 1,825,490 The aggregate intrinsic value in the table above represents the pretax intrinsic value, which is calculated as the difference between the exercise price of the stock options and the fair value of the Common Stock. During the year ended December 31, 2021, 1,614,683 stock options were granted, including (a) 1,255,959 stock options granted to employees and directors of the Company, with a weighted average grant date fair value of $4.466 and (b) 358,724 stock options granted to a non-employee consultant of the Company, with a weighted average grant date fair value of $3.885. The vesting terms of these stock options are such that 25% vest on the one-year anniversary of the date of grant and the remaining 75% vest ratably over the remaining three years. The vesting terms of the grant to the non-employee consultant were such that 25% of the options vested immediately upon grant, 10% vesting on the first anniversary of the date of the grant and the remaining 65% vesting based on certain performance milestones. Upon completion of the Business Combination, the remaining 269,043 unvested stock options immediately vested and all remaining unrecognized stock-based compensation expense associated with these stock options was recorded. During the year ended December 31, 2020, 2,364,010 stock options were granted, including: (a) 571,774 stock options granted to employees and directors of the Company, with a weighted average grant date fair value of $3.350 and (b) 1,792,236 stock options to non-employee consultants of the Company, with a weighted average grant date fair value of $0.714. Of the stock options granted to employees and directors of the Company, 125,553 stock options vested in full upon ninety days after the grant date and 446,221of such stock options vest 25% on the one-year anniversary of the date of grant and the remaining 75% vest ratably over the remaining three years. Of the stock options granted to non-employee consultants of the Company, 64,570 stock options vested in full upon the grant date and 1,727,666 of such stock options vest 25% on the one-year anniversary of the date of grant and the remaining 75% vest ratably over the remaining three years. During the year ended December 31, 2021, a non-employee consultant of the Company exercised 64,570 stock options with an intrinsic value of $nil, resulting in the issuance of 64,570 shares of Common Stock for cash proceeds of $450,000. As of December 31, 2021, the unrecognized share-based compensation expense related to unvested options, was $5,778,699 and the estimated weighted average remaining vesting period was 2.4 years (December 31, 2020, the unrecognized share-based compensation expense related to unvested options, was $1,433,785 and the estimated weighted average remaining vesting period was 3.1 years).

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies Property, in development commitment The Company entered into agreements for the engineering design and modification of its facility in Indianapolis, Indiana, which is recorded in property, in development. As at December 31, 2021, the Company is committed to future payments of approximately $5.6 million, relating to the continued construction and retrofit of the building. During the years ended December 31, 2021 and December 31, 2020 approximately $6.1 million and $4.9 million, respectively, has been recorded within property, plant and equipment in connection with these agreements. Clinical trial and commercial commitments The Company in the normal course of business enters into various services and supply agreements in connection with its clinical trials to ensure the supply of certain product and product lines during the Company’s clinical phase. These agreements often have minimum purchase commitments and generally terminate upon the termination of the clinical trial. Minimum purchase commitments under these agreements include individual commitments up to $3.8 million. Aggregate remaining minimum commitments amount to approximately $6.8 million with payments ranging from three The Company also has a supply agreement with a third party to purchase certain products for use in the Company’s full scale production process. The Company is committed to purchase a minimum quantity of product in the amount of approximately $49.8 million ($62.9 million CAD) over the remaining contract term. The purchase commitments are contingent upon the completion of certain milestones by the third-party supplier. The Company recorded $nil in connection with this agreement during the year ended December 31, 2021 (year ended December 31, 2020 – $nil). The Company also has an agreement with a third party to provide certain services in connection with the Company’s SPLASH clinical phase study. The agreement expires on the date of the completion or termination of the clinical trial. The remaining minimum purchase commitment under this agreement is approximately $46.4 million with payments that range from one

License agreements

License agreements	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License agreements	License agreements License agreement with Scintomics GMBH (“SCI”) In November 2019, the Company entered into a sublicense agreement with SCI (“SCI Agreement). Under the SCI Agreement, the Company was granted an exclusive, sublicensable, worldwide (other than the Middle East and Asia) license under SCI’s patent rights to use, develop, manufacture and commercialize any products arising from SCI’s patent rights related to PSMA ligands for imaging and endoradiotherapy. Under the SCI Agreement, the Company is obligated to make aggregate milestone payments to SCI of up to $26,800,000 (€23,500,000), upon the achievement of specified development and regulatory milestones. The Company is also obligated to pay a low-teens percentage royalty related to the annual net sales by the Company and any of its affiliates and sublicensees. Royalties will be paid by the Company on a country-by country basis beginning upon the first commercial sale in such country. There is also an additional low thirties percentage fee payable to SCI for monetary payments arising from the grant of a sublicense to a sublicensee or in the form of other benefits. The Company has the right to terminate the agreement, subject to a prior notice of five months, with a termination fee of approximately $1,400,000 (€1,250,000) unless the first milestone payment has already been paid. If the Company or SCI fails to comply with any of its obligations or otherwise breaches the agreement, the other party may terminate the agreement. During the year ended December 31, 2021, the Company did not make any payments to SCI or recognize any research and development expenses under the SCI Agreement. During the year ended December 31, 2020 the Company made a payment to SCI of approximately $1,520,000 upon the achievement of a specified development milestone and recognized this amount as a research and development expense in its Consolidated Statements of Operations. Research and license agreements with Bach Sciences LLC (“BACH”) First BACH Agreement In April 2020, the Company entered into a sublicense and collaboration agreement with BACH to develop and commercialize a radiopharmaceutical agent (“BACH Agreement). On September 24, 2021, POINT Biopharma Inc. entered into a third amendment (the “Third Amendment”) to that certain Exclusive Sublicense Agreement, dated April 2, 2020, between POINT Biopharma Inc. and BACH as amended by the First Amendment to Exclusive Sublicense Agreement, dated April 14, 2020, and the Second Amendment to Exclusive Sublicense Agreement, dated January 5, 2021 (collectively, the “Sublicense Agreement”). The Sublicense Agreement grants to POINT Biopharma Inc. an exclusive, sublicensable, worldwide license under BACH's patent rights to use, develop, manufacture and commercialize any products arising from the licensed technology. Pursuant to the Third Amendment, POINT Biopharma Inc. exercised its option (the “Commercialization Option”) under the Sublicense Agreement to acquire a worldwide exclusive, royalty bearing license to commercialize any products and processes from uses of patent rights for FAP-targeted radiopharmaceuticals. The Third Amendment also amended the Sublicense Agreement to provide the Company with the first option (the “Invention Option”) to acquire a worldwide exclusive royalty bearing license to BACH's patent rights, materials and know-how with respect to new inventions directed to FAP-targeted radiopharmaceuticals. As partial consideration for the exercise of the Commercialization Option and the grant of the Invention Option under the Third Amendment, POINT Biopharma Inc. paid, upon execution of the Sublicense Agreement, an option exercise fee of $3,250,000. POINT Biopharma Inc. is also required to make regular quarterly contributions up to a specified amount to BACH's specified research and development until June 1, 2022 and October 1, 2022, in each case, commencing on October 1, 2021. The Company is obligated to make the aggregate milestone payments of up to $8,000,000 to BACH upon the achievement of specified development and regulatory milestones and up to $38,000,000 upon the achievement of specified sales milestones under the BACH Agreement. The Company is also obligated to pay a low-teens percentage royalty related to the annual net sales of each licensed products or licensed process covered by a valid claim, but reduced to a single digit percentage royalty related to net sales in the absence of a Valid Claim by the Company and any of its affiliates and sublicensees based on its global sales. Royalties will be paid by the Company on a country-by country basis beginning upon the first commercial sale in such country. There is also an additional low- teens to mid-twenties percentage sublicense fee payable to BACH for monetary payments arising from a grant of a sub-license to a sub-licensee or in the form of other benefits, depending on the specified development stage of the product. During the year ended December 31, 2021, the Company made a payment to BACH of $3,250,000 related to the Commercialization Option discussed above and recognized this amount as research and development expenses in its Consolidated Statements of Operations (December 31, 2020 – payments of $600,000 were recorded as research and development expenses). During the year ended December 31, 2021, the Company also made payments for the sponsored research agreements in the amount of $1,250,000 (December 31, 2020 – $750,000), which are recognized as research and development expenses in the Company’s Consolidated Statements of Operations. Second BACH Agreement In December 2020, the Company entered into a sublicense and collaboration agreement with BACH to develop and commercialize compounds that leverage a proprietary technology platform (“Second BACH Agreement’”). Under the Second BACH Agreement, the Company was granted an exclusive, sublicensable, worldwide license under BACH’s patent rights to use, develop, manufacture and commercialize any products arising from the patent related to the synthetic compound. For an exclusive commercialization option, the Company paid an upfront fee of $200,000 in January 2021, which was recognized as research and development expense during the year ended December 31, 2020. The Company is further obligated to make aggregate milestone payments to BACH of up to $3,000,000 for the first product developed, upon the achievement of specified development and regulatory milestones and of up to $45,000,000 upon the achievement of specified sales milestones. For subsequent products, the Company is obligated to make a milestone payment to BACH of up to $1,000,000 for major market regulatory approval and of up to $45,000,000 upon the achievement of specified sales milestones. The Company is also obligated to pay a low-teens percentage royalty related to net sales of each licensed product or licensed process covered by a valid claim, but reduced to a single digit percentage royalty related to net sales in the absence of a valid claim. Royalty payments will be reduced in an amount equal to 100% of royalty fees paid to Avacta (defined below) for the same licensed product. Royalties will be paid by the Company on a country-by country basis beginning upon the first commercial sale in such country. There is also an additional low-teens to mid-twenties percentage sublicense fee payable to BACH for monetary payments arising from a grant of a sub-license to a sub-licensee or in the form of other benefits, depending on the specified development stage of the product. During the year ended December 31, 2021, the Company made payments for the sponsored research agreement in the amount of $800,000 as a research and development expense (December 31, 2020 – the Company recognized the upfront fee of $200,000 as research and development expense). License agreement with Avacta Lifesciences Limited (“ Avacta ”) In December 2020, the Company entered into an agreement with Avacta (“Avacta Agreement”), which is directly related to the second BACH agreement above. Under the Avacta Agreement, the Company became a sublicensee of Avacta’s license for using intellectual property related to developing and marketing FAP-activated radiopharmaceutical agents. Under this agreement, the Company obtained an exclusive license of Avacta’s patent rights to use, develop, manufacture and commercialize any products arising from the patent. The Company has the right to grant sublicenses of its rights. The Company is obligated to pay an upfront payment of $1,000,000 for the initial license fee. The Company is further obligated to make aggregate milestone payments to Avacta of up to $4,500,000, upon the achievement of specified development milestones for its first product and up to $3,000,000 each for any additional products developed with the technology upon reaching the specified development milestones. In addition, the Company is obligated to pay a milestone payment of $5,000,000 for each product for the regulatory milestone being approved in specified territories. The Company is also obligated to pay a single digit percentage royalty (subject to a reduction on certain conditions) related to the annual net sales by the Company, its affiliates or its sublicensees for each licensed product or license process and a single digit percentage royalty on a specified product arising out of the patents. The royalty rate will be reduced by 50% for net sales occurring in the U.S. if there is no valid claim at the time of sale. There is also an additional single digit percentage fee payable to Avacta for monetary payments arising from a grant of a sublicense to a sublicensee or in the form of other benefits. During the year ended December 31, 2021, the Company recognized the last three installments of the initial license fee of $750,000 as a research and development expense (December 31, 2020 – the first installment of the initial license fee of $250,000 was recognized as a research and development expense). License agreement with Canadian Molecular Probe Consortium (“CanProbe”) In December 2020, the Company entered into a license agreement with CanProbe (“CanProbe Agreement”). Under the CanProbe Agreement, the Company was granted an exclusive, sublicensable and worldwide license under CanProbe’s patent rights to use, develop, manufacture and commercialize any products arising from a patent associated with the process for the production of 177 Lu. Under the CanProbe Agreement, the Company paid an upfront fee of approximately $386,000 ($500,000 CAD) for the execution of the agreement and a further payment of approximately $188,000 ($250,000 CAD), which will be credited against the first milestone payment. The Company is obligated to make aggregate milestone payments to CanProbe of up to $2,573,000 ($3,250,000 CAD) upon the achievement of receiving marketing authorization milestones for specified territories. The Company is also obligated to pay a single digit royalty related to the annual net sales by the Company and any of its affiliates and sublicensees. Royalties will be paid by the Company on a country-by country basis beginning upon the first commercial sale in such country. There is also an additional low-teens percentage fee payable to CanProbe for monetary payments arising from a grant of a sublicense to a sublicensee or in the form of other benefits. In the event it is necessary for the Company or its sublicensees to sell the product in a sub-territory or to obtain a license and to pay royalties to one or more third parties on net-sales, and if the aggregate royalty burden payable is greater than a high single digit percent of net-sales, then the Company may reduce the royalty fees or sub-licensing fees for sales of such product by 50% of royalties actually paid to the third party on net sales of the product in the territory in the same royalty period. During the year ended December 31, 2021, the Company did not make any payments to CanProbe or recognize any research and development expenses under the CanProbe Agreement (December 31, 2020 – the Company recognized the contract execution fees of $574,000 as research and development expense). L icense agreement with Belgian Nuclear Research Centre (“SCK-CEN”) On June 30, 2021, the Company entered into a license agreement with the Belgian Nuclear Research Centre (“SCK-CEN”). Under the SCK-CEN Agreement, the Company was granted a worldwide, royalty-bearing, non-exclusive, sublicensable license under SCK-CEN’s patent rights to develop, make, have made, use and import n.c.a 177 Lu using SCK-CEN Technology. The Company is obligated to make aggregate milestone payments to SCK-CEN of up to $125,000 (€110,000) upon the achievement of certain technology implementation milestones. The Company is also obligated to

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income taxes	Income taxes Domestic and international pre-tax loss consists of the following: Year ended December 31, 2021 Year ended December 31, 2020 $ $ U.S. 46,225,053 13,591,329 Canada (628,230) (306,208) Loss before provision for income taxes 45,596,823 13,285,121 Income tax expense attributable to operations is comprised of the following: Year ended December 31, 2021 Year ended December 31, 2020 $ $ Current income tax: Federal 75 10,000 State (114) 4,114 Foreign 240,105 73,768 Total current expense 240,066 87,882 Deferred income tax: Federal — — State — — Foreign 65,592 — Total deferred expense 65,592 — Total provision for income tax 305,658 87,882 A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows: Year ended December 31, 2021 Year ended December 31, 2020 $ $ Provision for income taxes at the Company’s statutory tax rate of 21% (9,575,333) (2,789,875) State income taxes, net of federal tax benefit (1,496,432) (574,046) Change in valuation allowance 10,570,870 3,412,396 Permanent items and other 806,553 39,407 Provision for income taxes at the Company’s effective income tax rate 305,658 87,882 Due to the existence of the valuation allowance, future recognition of previously unrecognized tax benefits will not impact the Company’s effective tax rate. The Company is subject to taxation in the U.S., Canada and various state jurisdictions. All of the Company’s tax years from inception are subject to examination by federal, and state tax authorities. The Company’s practice is to recognize interest and penalties related to income tax matters in income tax expense. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows: Year ended December 31, 2021 Year ended December 31, 2020 $ $ Net operating loss carryforwards 12,909,104 1,910,665 License agreements 1,763,889 967,268 Start-up costs 233,205 13,679 Share based compensation 811,236 422,280 Reserves and accruals 266,480 45,110 Other 74,763 55,889 Total deferred tax assets 16,058,677 3,414,891 Valuation allowance (16,054,274) (3,414,891) Net deferred tax assets 4,403 — Deferred tax liabilities Unrealized exchange gain (69,995) — Total deferred tax liabilities (69,995) — Net deferred tax liabilities (65,592) — Deferred income tax assets and liabilities are recorded for differences between the financial statement and tax basis of the assets and liabilities that will result in taxable or deductible amounts in the future based on enacted laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has evaluated the available evidence supporting the realization of its U.S. gross deferred tax assets, including the amount and timing of future taxable income, and has determined it is more likely than not that the assets will not be realized. As a result, the Company has concluded that a full valuation allowance against its U.S. deferred tax assets is necessary at this time. As of December 31, 2021, the Company has federal and state net operating loss carryforwards of approximately $53.0 million and $41.9 million, respectively. As a result of the Tax Cuts and Jobs Act of 2017, for U.S. income tax purposes, net operating losses generated after December 31, 2017 can be carried forward indefinitely, but are limited to 80% utilization against future taxable income each year. Of the amount of federal net operating loss carryforwards, $53.0 million can be carried forward indefinitely. Unless previously utilized, the state net operating losses will begin to expire in 2030. As of December 31, 2021, the Company has $0.1 million of Indiana Hoosier Business tax credits that begin to expire in 2029. The Company has not yet conducted a study to document whether its research activities may qualify for the research and development tax credit. Such a study may result in the creation of a research and development credit carryforward; however, until a study is completed, no amount is being presented as a deferred tax asset or as an uncertain tax position. Any research and development credit carryforward identified and claimed if and when such study is complete would be offset by an adjustment to the valuation allowance. Pursuant to the Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company's NOL and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an ownership change analysis pursuant to IRS Section 382. If ownership changes have occurred or occurs in the future, the amount of remaining tax attribute carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance. Uncertain tax positions are evaluated based upon the facts and circumstances that exist at each reporting period. Subsequent changes in judgement based upon new information may lead to changes in recognition, derecognition, and measurement. Adjustment may result, for example, upon resolution of an issue with the taxing authorities or expiration of a statute of limitations barring an assessment for an issue. The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination by tax authorities. As of December 31, 2021, and 2020, the Company had no uncertain tax positions. The Company had no accrued interest or penalties related to income tax matters in the Company’s balance sheet at December 31, 2021, and has not recognized interest or penalties in the Company’s statement of operations and comprehensive loss for the year ended December 31, 2021. Further, the Company is not currently under examination by any federal, state or local tax authority. The Company does not record U.S. income taxes on the undistributed earnings of its foreign subsidiaries based upon the Company's intention to permanently reinvest undistributed earnings to ensure sufficient working capital and further expansion of existing operations outside the U.S. In the event the Company is required to repatriate funds from outside of the U.S., such repatriation would be subject to local laws, customs, and tax consequences. The Tax cut and jobs Act subjects a U.S. shareholder to tax on GILTI earned by certain foreign subsidiaries. The Company has elected to account for GILTI in the year the tax is incurred in accordance with the FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, which states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was passed into law. The CARES Act includes several significant business tax provisions including modification to the taxable income limitation for utilization of net operating losses incurred in 2019 to 2021, an increase to the limitation on deductibility of certain business interest expense, bonus depreciation for purchases of qualified improvement property and special deductions on certain corporate charitable contributions. The Company analyzed the provisions of the CARES Act and determined there was no impact to its income tax provision for the years ended December 31, 2021 and 2020.

Net loss per share

Net loss per share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net loss per share	Net loss per share Basic loss earnings per share is computed by dividing the loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per share is computed by dividing loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued, using the treasury stock method. Year ended December 31, 2021 Year ended December 31, 2020 Net loss attributable to common stockholders 45,902,481 13,373,003 Weighted-average common shares outstanding – basic and diluted 73,850,822 38,875,643 Net loss per share attributable to common stockholders – basic and diluted $ 0.62 $ 0.34 The Company’s potentially dilutive securities, which include stock options and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential shares of Common Stock, presented based on amounts outstanding at the year ended December 31, 2021, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Year ended December 31, 2021 Year ended December 31, 2020 Options to purchase shares of Common Stock 3,825,751 2,364,010 Warrants to purchase shares of Common Stock — 2,869,799 3,825,751 5,233,809

Financial instruments risk mana

Financial instruments risk management	12 Months Ended
	Dec. 31, 2021
Risks and Uncertainties [Abstract]
Financial instruments risk management	Financial instruments risk management Concentration risk The Company currently holds all its cash deposits with one financial institution. The financial institution is a large and high-quality investment grade institution. The Company will continue to monitor for changes in credit quality in relation to the counterparties to which it has relationships. Foreign currency risk The Company does not have significant operating subsidiaries or significant investments in foreign countries as of December 31, 2021 and 2020. The Company is subject to foreign currency exposure on its cash balances, accounts payable and accrued liabilities denominated in currencies other than the U.S. dollar, expenses incurred from certain supplier and service agreements denominated in Canadian dollars and Euro, as well as salaries and wages in respect of the Company’s Canadian employees. The Company does not currently manage its foreign currency exposure through hedging programs and will continue to monitor its foreign currency assets and liabilities and evaluate the needs for these programs in the future. During the years ended December 31, 2021 and 2020, the Company recorded $73,153 and $164,962, respectively, of foreign currency losses in the consolidated statements of operations. Interest rate risk The Company was previously subject to interest rate risk under its Mortgage loan. The Mortgage bore interest at 2.85% plus a minimum rate of 1-month LIBOR, subject to a LIBOR floor of 0.25%. The Mortgage required quarterly interest payments, which commenced on October 1, 2020, with the principal amount originally due at maturity on January 10, 2022. For more details around the Mortgage see Note 8. The Company does not currently manage interest rate exposure through hedging programs. The Company will continue to monitor and evaluate the need for interest rate hedging programs in the future.

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related party transactions	Related party transactionsThe Company recognized expenses in connection with related party transactions in the consolidated statements of operations as follows: Year ended December 31, 2021 Year ended December 31, 2020 $ $ Share-based compensation for consulting arrangement — 1,109,776 Consulting fees to stockholder — 164,812 Consulting fees on business activities to Board member 235,095 90,975 Reimbursement to Board member for occupancy costs 73,894 21,315 308,989 1,386,878 Transactions with related parties are in the normal course of operations and have been measured at their agreed upon exchange amount. During the year ended December 31, 2020, the Company issued stock options to stockholders of a related party in exchange primarily for legal and financial consulting services. No amounts are owing in respect of these services as at December 31, 2021. During the years ended December 31, 2021 and December 31, 2020, the Company received consulting services for research and development from a Board member, for which approximately $73,000 is recorded within accrued liabilities as of December 31, 2021. In addition, during the year ended December 31, 2020, the Company received consulting services for manufacturing planning from a stockholder. No amounts are owing in respect of these services as of December 31, 2021. The Company currently has a lease arrangement in place with a Board member for the use of office space. The arrangement does not have a defined contractual lease term and is payable monthly. The Company has applied the short-term lease exemption under ASC Topic 842, Leases to this arrangement and is recording the lease payments of approximately $6,000 monthly as rent expense.

Employee benefit plan

Employee benefit plan	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Employee benefit plan	Employee benefit planThe Company maintains a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code for its U.S. employees. The plan allows eligible employees to defer, at the employee’s discretion, pretax compensation up to the IRS annual limits. The Company matched contributions up to 50% of the first 4% of the eligible employee’s compensation or the maximum amount permitted by law. Total expense for contributions made to U.S. employees was $45,715 for the year ended December 31, 2021 (December 31, 2020 - $2,787).

Subsequent events

Subsequent events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent events	Subsequent events Pursuant to the 2021 EIP, the aggregate number of shares of POINT Common Stock that may be issued pursuant to share awards shall be cumulatively increased annually on the first day of each fiscal year beginning with the 2022 fiscal year in an amount equal to four percent (4%) of shares of Common Stock outstanding on the last day of the immediately preceding fiscal year or a lesser number of shares determined by the Board. As a result, on January 1, 2022, an additional 3,604,871 shares added to the 2021 EIP.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma Corp., POINT Biopharma USA, Inc. and West 78th Street, LLC, for financial information and pursuant to the rules and regulations of the SEC. All intercompany accounts and transactions have been eliminated in consolidation.
Going Concern	These consolidated financial statements and accompanying notes have been prepared in accordance with the provisions of ASC Topic 205-40, Presentation of Financial Statements—Going Concern on the basis that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities an commitments in the normal course of business.
Risks and uncertainties	Risks and uncertainties The Company has incurred significant net losses since inception and, prior to the Business Combination, has funded operations through equity financings. Operating losses and negative cash flows are expected to continue for the foreseeable future. As losses continue to be incurred, the Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of the COVID-19 coronavirus, the impact of the Russo-Ukrainian conflict, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
Use of estimates	Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuations of stock options and warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Foreign currency and currency translation	Foreign currency and currency translation The reporting currency of the Company is the U.S. dollar. The functional currency of the Company’s legal entities including its parent is also the U.S. dollar. As a result, the Company records no cumulative translation adjustments related to translation of unrealized foreign exchange gains or losses. Realized foreign exchange gains and losses that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income (expense), net in the consolidated statements of operations, as incurred.
Fair value of financial instruments	Fair value of financial instruments Cash and cash equivalents are carried at fair value. Other financial instruments, including accounts payable and mortgage payable, are carried at amortized cost, which approximates fair value given their short-term nature.
Fair value measurements	Fair value measurements Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1 — Quoted prices in active markets for identical assets or liabilities. Cash and cash equivalents fall within level 1 of the fair value hierarchy. • Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid instruments with an original maturity of three months or less as cash equivalents.
Property in development	Property in development Property in development includes the purchase price of the land and building for the Company’s manufacturing facility in Indianapolis, Indiana, plus other acquisition-related costs. The Company also capitalizes all direct costs relating to the development of this property including interest on its mortgage borrowings and direct development costs identified with the property. Once the asset is complete and available for use, the costs of construction are transferred to the appropriate category of property, plant and equipment, and depreciation commences.
Leases	Leases Currently, the Company only holds short term leases and has elected to apply the short-term lease exemption. For all future lease arrangements, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement and in accordance with the guidance of ASC 842. Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. The Company currently does not have financing leases. The Company has elected not to recognize leases with an original term of one year or less on the consolidated balance sheets. Options to renew or early terminate a lease are included in the initial lease term of a lease when there is reasonable certainty that the option will be applied. The Company’s lease expense is recognized in the consolidated statements of operations according to its use in either research and development expenses or general administrative expenses. Currently, all lease expense is recorded in general and administrative expense.
Warrants	Warrants Common share purchase warrants entitle the holder to acquire common shares of the Company at a specified price for a specified period of time, which are classified as equity. Warrants are measured at the date of issuance using the Black-Scholes-Merton option pricing model. On January 28, 2021, all outstanding warrants to purchase common shares of the Company were exercised resulting in cash proceeds of $20,000,000.
Research and development costs	Research and development costs Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including costs for salaries and bonuses, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, share-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered. Upfront payments under license agreements are expensed as research and development expense upon receipt of the license, and annual maintenance fees under license agreements are expensed in the period in which they are incurred. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable.
Acquired in-process research and development expense	Acquired in-process research and development costs The Company has entered into various research, development and manufacturing contracts with research institutions and other companies. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. The upfront payments to acquire a new drug compound, as well as subsequent milestone payments, are immediately expensed as acquired in-process research and development, provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use. Once regulatory approval is received, payments to acquire rights, and the related milestone payments, are capitalized and the amortization of such assets recorded to product cost of sales.
Share-based compensation expense	Share-based compensation expense The Company recognizes share-based compensation expense for all share-based awards made to employees, directors and consultants based on estimated fair values. The Company determines share-based compensation on the grant date using the Black-Scholes-Merton option pricing model. The value of the award is recognized as expense on a straight-line basis over the requisite service period. ASC 718 - Stock Compensation ("ASC 718") allows for forfeitures to be recognized in the period in which they occur. ASC 718 aligns the accounting for share-based payments to non-employees with that of employees, with certain exceptions.
Income taxes	Income taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company may be entitled to investment tax credits in connection with its research and development costs. These investment tax credits are non-refundable tax credits and are accounting for in accordance with the Company’s income tax accounting policies.
Net income (loss) per share	Net income (loss) per share Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding warrants and stock options are considered potential dilutive common shares.
Segment information	Segment information The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company’s focus is on the development of radioligand therapy for the treatment of cancer.
Recent accounting pronouncements not yet effective	Recent accounting pronouncements not yet effective Debt with Conversion and Other Options The FASB has issued ASU 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible instruments, such as convertible debt or convertible preferred stock, by eliminating two potential methods in accounting for the embedded conversion feature. The standard also removes certain conditions previously used to evaluate whether a freestanding financial instrument, or certain types of embedded features, are considered to be settled in the issuer’s own equity. Finally, ASU 2020-06 requires that an entity use the if-converted method in calculating the effects of convertible instruments on diluted earnings per share, with one limited exception. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than for fiscal years beginning after December 15, 2020. The Company is currently evaluating the effects of this guidance. Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options The FASB has issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) . ASU 2021-04 provides guidance that an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. The standard also provides guidance on how an entity should measure and recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2021. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently evaluating the effects of this guidance. Government Assistance The FASB has issued ASU 2021-10, Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance . ASU 2021-10 provides guidance to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2021. Early application of the amendments is permitted. The Company is currently evaluating the effects of this guidance.

Business Combination (Tables)

Business Combination (Tables)	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Summary of net proceeds from the Business Combination	The following table summarizes the elements of the net proceeds from the Business Combination: Recapitalization Cash - RACA Trust and cash (net of redemptions) $ 121,770,367 Cash - PIPE Financing 165,000,000 Less: Underwriting fees, costs incurred by RACA and other direct and incremental costs, each paid prior to December 31, 2021 (21,887,685) Net proceeds from the Business Combination, net of costs incurred by RACA and direct and incremental costs paid per the statement of cash flows $ 264,882,682
Summary of number of shares of common stock outstanding immediately following the consummation of the Business Combination	The following table summarizes the number of shares of Common Stock outstanding immediately following the consummation of the Business Combination: Number of RACA Class A and Class B shares outstanding prior to the Business Combination 16,039,769 Class A shares issued pursuant to the PIPE Financing 16,500,000 Common Stock issued upon conversion of RACA Class A Common Stock and Class B Common Stock and PIPE Financing shares 32,539,769 Common Stock issued upon conversion of POINT Biopharma Inc. common shares 57,582,025 Total shares of Common Stock outstanding immediately following the Business Combination 90,121,794

Prepaid expenses and other cu_2

Prepaid expenses and other current assets (Tables)	12 Months Ended
	Dec. 31, 2021
Prepaid Expense and Other Assets, Current [Abstract]
Summary of prepaid expenses and other current assets	Prepaid expenses and other current assets consisted of the following: As at December 31, As at December 31, $ $ Insurance 2,175,379 — Prepaid clinical trial expenses 1,973,609 1,763,731 Deposit on production equipment 703,461 — Canadian harmonized sales tax receivable 72,666 58,982 Other 105,450 27,633 Total 5,030,565 1,850,346

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Summary of property, plant and equipment, net	Property, plant and equipment consisted of the following: As at December 31, As at December 31, $ $ Property in development 16,561,032 9,797,400 Machinery and equipment 2,132,768 — Furniture and fixtures 590,545 — Computer equipment 127,741 — Total 19,412,086 9,797,400

Accounts payable (Tables)

Accounts payable (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Accounts payable	Accounts payable consisted of the following: As at December 31, As at December 31, $ $ Accounts payable 1,730,304 3,595,745 Other payables 8,166 889 Total 1,738,470 3,596,634

Accrued expenses (Tables)

Accrued expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Accrued Liabilities, Current [Abstract]
Summary of accrued liabilities	Accrued liabilities consisted of the following: As at December 31, As at December 31, $ $ Accrued personnel costs 3,440,558 540,292 Accrued research and development costs 1,142,056 597,994 Accrued costs for the purchases of property, plant and equipment 648,196 — Accrued corporate legal fees and other professional services 654,945 210,099 Other accrued costs 104,761 130,656 Total 5,990,516 1,479,041

Stockholders_ equity (Tables)

Stockholders’ equity (Tables)	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Fair Value Measurement Inputs and Valuation Techniques	The Company valued the warrants using the Black-Scholes-Merton option pricing model with the following inputs: Year ended December 31, 2020 Risk-free interest rate 0.13 % Expected term (in years) 1 Expected volatility 65 % Expected dividend yield 0 %

Share-based compensation (Table

Share-based compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Summary of share-based compensation expense	Share-based compensation expense for the years ended December 31, 2021 and 2020 was recognized in the Consolidated Statements of Operations as follows: Year ended December 31, 2021 Year ended December 31, 2020 $ $ Research and development 1,899,471 398,139 General and administrative 403,136 1,362,667 Total share-based compensation expense 2,302,607 1,760,806
Summary of assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted	The following table presents the assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted: Year ended December 31, 2021 Year ended December 31, 2020 Risk-free interest rate 0.66% – 1.16% 0.11% – 0.50% Expected term (in years) 4.25 – 5.38 0.35 – 4.25 Expected volatility 65% – 73% 65% Expected dividend yield 0% 0%
Summary of stock option activity	The following table summarizes the activity relating to the Company’s options to purchase stock. The below stock option figures are presented giving effect to a retroactive application of the Business Combination which resulted in a replacement of the previous POINT Biopharma Inc. stock options with stock options of the Company, as described above, at a conversion ratio of approximately 3.59:1. In addition, the exercise price for each replacement stock option is also adjusted using the ratio of approximately 3.59:1. See Note 3 for additional details: Number of Weighted Weighted- Aggregate Outstanding as of December 31, 2020 2,364,010 2.88 Granted 1,614,683 7.81 Exercised (64,570) 6.97 Forfeited (88,372) 7.80 Outstanding as of December 31, 2021 3,825,751 4.78 5.2 7,302,047 Vested and expected to vest as of December 31, 2021 3,825,751 4.78 5.2 7,302,047 Options exercisable as of December 31, 2021 1,018,775 4.60 6.0 1,825,490

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Summary of loss before provision for income taxes	Domestic and international pre-tax loss consists of the following: Year ended December 31, 2021 Year ended December 31, 2020 $ $ U.S. 46,225,053 13,591,329 Canada (628,230) (306,208) Loss before provision for income taxes 45,596,823 13,285,121
Summary of provision for income taxes	Income tax expense attributable to operations is comprised of the following: Year ended December 31, 2021 Year ended December 31, 2020 $ $ Current income tax: Federal 75 10,000 State (114) 4,114 Foreign 240,105 73,768 Total current expense 240,066 87,882 Deferred income tax: Federal — — State — — Foreign 65,592 — Total deferred expense 65,592 — Total provision for income tax 305,658 87,882
Summary of reconciliation of the United States federal statutory income tax rate to the Company's effective income tax rate	A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows: Year ended December 31, 2021 Year ended December 31, 2020 $ $ Provision for income taxes at the Company’s statutory tax rate of 21% (9,575,333) (2,789,875) State income taxes, net of federal tax benefit (1,496,432) (574,046) Change in valuation allowance 10,570,870 3,412,396 Permanent items and other 806,553 39,407 Provision for income taxes at the Company’s effective income tax rate 305,658 87,882
Summary of net deferred tax assets	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows: Year ended December 31, 2021 Year ended December 31, 2020 $ $ Net operating loss carryforwards 12,909,104 1,910,665 License agreements 1,763,889 967,268 Start-up costs 233,205 13,679 Share based compensation 811,236 422,280 Reserves and accruals 266,480 45,110 Other 74,763 55,889 Total deferred tax assets 16,058,677 3,414,891 Valuation allowance (16,054,274) (3,414,891) Net deferred tax assets 4,403 — Deferred tax liabilities Unrealized exchange gain (69,995) — Total deferred tax liabilities (69,995) — Net deferred tax liabilities (65,592) —

Net loss per share (Tables)

Net loss per share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Summary of basic and diluted net loss per share	Year ended December 31, 2021 Year ended December 31, 2020 Net loss attributable to common stockholders 45,902,481 13,373,003 Weighted-average common shares outstanding – basic and diluted 73,850,822 38,875,643 Net loss per share attributable to common stockholders – basic and diluted $ 0.62 $ 0.34
Summary of potential common shares excluded from the computation of diluted net loss per share because of anti-dilutive effect	The Company excluded the following potential shares of Common Stock, presented based on amounts outstanding at the year ended December 31, 2021, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Year ended December 31, 2021 Year ended December 31, 2020 Options to purchase shares of Common Stock 3,825,751 2,364,010 Warrants to purchase shares of Common Stock — 2,869,799 3,825,751 5,233,809

Related party transaction (Tabl

Related party transaction (Tables)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Schedule of related party transactions	The Company recognized expenses in connection with related party transactions in the consolidated statements of operations as follows: Year ended December 31, 2021 Year ended December 31, 2020 $ $ Share-based compensation for consulting arrangement — 1,109,776 Consulting fees to stockholder — 164,812 Consulting fees on business activities to Board member 235,095 90,975 Reimbursement to Board member for occupancy costs 73,894 21,315 308,989 1,386,878

Nature of business - Narrative

Nature of business - Narrative (Details)	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2021subsidiary$ / shares	Dec. 31, 2020$ / shares
Nature Of Business [Line Items]
Common shares, par value (in dollars per share)	$ 0.001	$ 0.0001	$ 0.0001
Number of wholly-owned subsidiaries | subsidiary		4
Private Placement
Nature Of Business [Line Items]
Sale of stock, price per share (in dollars per share)	$ 10
Sale of stock, consideration received on transaction | $	$ 165,000,000
Class A common shares
Nature Of Business [Line Items]
Common shares, par value (in dollars per share)	$ 0.0001
Class A common shares | Private Placement
Nature Of Business [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	16,500,000
Class B common shares
Nature Of Business [Line Items]
Common shares, par value (in dollars per share)	$ 0.0001
RACA
Nature Of Business [Line Items]
Business combination, entity shares issued per acquiree share (in shares) | shares	3.59
Exchange of common stock per share (in dollars per share)	$ 0.0001

Summary of significant accoun_3

Summary of significant accounting policies (Details)	Jan. 28, 2021USD ($)
Accounting Policies [Abstract]
Cash proceeds from exercise of warrants	$ 20,000,000

Business Combination (Details)

Business Combination (Details)	Jun. 30, 2021USD ($)shares	Dec. 31, 2021shares	Dec. 31, 2020shares
Business Acquisition [Line Items]
Exchange ratio	3.59
Common stock, shares issued (in shares) | shares		90,121,794	54,647,656
Common stock, shares outstanding (in shares) | shares		90,121,794	54,647,656
POINT Biopharma Inc
Business Acquisition [Line Items]
Implied vested equity value | $	$ 585,000,000
Exchange ratio	3.59
Number of common share of the company (in shares) | shares	1
PIPE Financing | $	$ 165,000,000
Number of common shares received for each share (in shares) | shares	16,500,000
Common stock, shares issued (in shares) | shares	90,121,794
Common stock, shares outstanding (in shares) | shares	90,121,794
Goodwill | $	$ 0
Other intangible assets | $	0
Acquisition related costs | $	21,900,000
Net proceeds excluding transaction costs | $	$ 4,700,000

Business Combination - Summary

Business Combination - Summary of Net proceeds (Details) - POINT Biopharma Inc	Jun. 30, 2021USD ($)
Business Acquisition [Line Items]
Cash - RACA Trust and cash (net of redemptions)	$ 121,770,367
Cash - PIPE Financing	165,000,000
Less: Underwriting fees, costs incurred by RACA and other direct and incremental costs, each paid prior to December 31, 2021	(21,887,685)
Net proceeds from the Business Combination, net of costs incurred by RACA and direct and incremental costs paid per the statement of cash flows	$ 264,882,682

Business Combination - Summar_2

Business Combination - Summary of Shares of Common Stock Issued (Details) - shares	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Total shares of Common Stock outstanding immediately following the Business Combination (in shares)	90,121,794		54,647,656
POINT Biopharma Inc
Business Acquisition [Line Items]
RACA Class A and Class B shares outstanding prior to the Business Combination (in shares)		16,039,769
Class A shares issued pursuant to the PIPE Financing (in shares)		16,500,000
Common Stock issued upon conversion of RACA Class A Common Stock and Class B Common Stock and PIPE Financing shares (in shares)	32,539,769	32,539,769
Common Stock issued upon conversion of POINT Biopharma Inc. common shares (in shares)		57,582,025
Total shares of Common Stock outstanding immediately following the Business Combination (in shares)		90,121,794

Cash and cash equivalents (Deta

Cash and cash equivalents (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 238,815,991	$ 10,546,749

Prepaid expenses and other cu_3

Prepaid expenses and other current assets (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Insurance	$ 2,175,379	$ 0
Prepaid clinical trial expenses	1,973,609	1,763,731
Deposit on production equipment	703,461	0
Canadian harmonized sales tax receivable	72,666	58,982
Other	105,450	27,633
Total	$ 5,030,565	$ 1,850,346

Property, plant and equipment_2

Property, plant and equipment (Details)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Jul. 10, 2020ft²
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 19,412,086	$ 9,797,400
Square-foot of building | ft²			81,000
Property in development
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	16,561,032	9,797,400
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	2,132,768	0
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	590,545	0
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 127,741	$ 0

Accounts payable (Details)

Accounts payable (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounts payable	$ 1,730,304	$ 3,595,745
Other payables	8,166	889
Total	$ 1,738,470	$ 3,596,634

Accrued expenses (Details)

Accrued expenses (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accrued Liabilities, Current [Abstract]
Accrued personnel costs	$ 3,440,558	$ 540,292
Accrued research and development costs	1,142,056	597,994
Accrued costs for the purchases of property, plant and equipment	648,196	0
Accrued corporate legal fees and other professional services	654,945	210,099
Other accrued costs	104,761	130,656
Total	$ 5,990,516	$ 1,479,041

Mortgage payable (Details)

Mortgage payable (Details)	Jul. 10, 2020USD ($)ft²	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Mortgage loan obtained	$ 3,562,500
Square-foot of building | ft²	81,000
Costs and fees incurred that are capitalized and recorded as finance costs over the life of the Mortgage	$ 17,194
LIBOR floor	0.25%
Interest costs		$ 63,195	$ 54,605
Amortization of debt issuance costs		$ 11,840	$ 5,354
LIBOR
Debt Instrument [Line Items]
Spread on variable rate	2.85%
LIBOR floor	0.25%

Stockholders_ equity (Details)

Stockholders’ equity (Details)	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Jun. 30, 2021$ / sharesshares	Dec. 31, 2019shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, authorized (in shares)	430,000,000	430,000,000
Exchange ratio			3.59
Common shares, par value (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001	$ 0.001
Proceeds from issuance of common stock and warrants | $	$ 20,450,000
Issuance of shares of Common Stock in connection with the Business Combination (see Note 3), net of direct and incremental costs paid | $	$ 264,882,682
Cost and fees on issuance of common shares | $		$ 324,555
Common stock, shares issued (in shares)	90,121,794	54,647,656
Common stock, shares outstanding (in shares)	90,121,794	54,647,656
Cash dividend declared | $	$ 0	$ 0
Cash dividend paid | $	0	$ 0
Sale Of Stock A
Accumulated Other Comprehensive Income (Loss) [Line Items]
Price per share (in dollars per share) | $ / shares		$ 0.01
Issuance of shares of Common Stock in connection with the Business Combination (see Note 3), net of direct and incremental costs paid | $		$ 133,754
Sale Of Stock B
Accumulated Other Comprehensive Income (Loss) [Line Items]
Price per share (in dollars per share) | $ / shares		$ 5
Issuance of shares of Common Stock in connection with the Business Combination (see Note 3), net of direct and incremental costs paid | $		$ 5,292,500
Sale Of Stock C
Accumulated Other Comprehensive Income (Loss) [Line Items]
Price per share (in dollars per share) | $ / shares		$ 25
Issuance of shares of Common Stock in connection with the Business Combination (see Note 3), net of direct and incremental costs paid | $		$ 20,000,000
Non-employee consultant
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares of Common Stock in connection with the Business Combination (see Note 3), net of direct and incremental costs paid | $	$ 450,000
POINT Biopharma Inc
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exchange ratio			3.59
Business combination and PIPE financing shares as converted into common stock (in shares)	32,539,769		32,539,769
Common stock, shares issued (in shares)			90,121,794
Common stock, shares outstanding (in shares)			90,121,794
Stock options
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)	64,570
Preferred shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred shares, shares authorized (in shares)	20,000,000
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001
Number of shares issued during period (in shares)	0	0
Common Stock
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)	800,000	54,647,656
Common stock, shares outstanding (in shares)	90,121,794	54,647,656		0
Common Stock | Sale Of Stock A
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)		13,375,384
Common Stock | Sale Of Stock B
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)		1,058,500
Common Stock | Sale Of Stock C
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)		800,000
Common Stock | Non-employee consultant
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)	18,000
Warrants
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)	2,869,799
Warrants | Sale Of Stock A
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)		47,980,765
Warrants | Sale Of Stock B
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)		3,797,096
Warrants | Sale Of Stock C
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)		2,869,795

Stockholders_ equity - Warrants

Stockholders’ equity - Warrants (Details) - USD ($)	Jan. 28, 2021	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares)			800,000
Exercise prices of each warrant (in dollars per share)			$ 25
Warrants issued to purchase shares of common stock (in shares)	800,000
Cash proceeds from exercise of warrants	$ 20,000,000
Issuance of warrants (in shares)			$ 2,526,320
Warrants
Class of Warrant or Right [Line Items]
Number of shares issued during period (in shares)		2,869,799

Stockholders_ equity - Pricing

Stockholders’ equity - Pricing model (Details)	Dec. 31, 2020
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0.0013
Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years)	1 year
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0.65
Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0

Stockholders_ equity - Warran_2

Stockholders’ equity - Warrants exercised (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Stockholders' Equity Note [Abstract]
Issuance of warrants (in shares)	$ 2,526,320

Share-based compensation - Narr

Share-based compensation - Narrative (Details) - USD ($)	Jan. 01, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance under plan (in shares)		7,438,527
Annual increase in shares authorized, percentage		4.00%
Number of additional shares authorized for issuance under plan (in shares)	3,604,871
Expiration period		6 years
Tax benefit related to share-based compensation expense		$ 0	$ 0
Unvested stock options, vested (in shares)		269,043
Issuance of shares of Common Stock in connection with the Business Combination (see Note 3), net of direct and incremental costs paid		$ 264,882,682
Unrecognized share-based compensation expense		$ 5,778,699	$ 1,433,785
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of shares of Common Stock in connection with stock option exercises (in shares)		64,570
Vesting on 1st year anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Vesting percentage		25.00%
Vesting ratably over the remaining three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Non-employee consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of shares of Common Stock in connection with the Business Combination (see Note 3), net of direct and incremental costs paid		$ 450,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)		1,614,683	2,364,010
Issuance of shares of Common Stock in connection with stock option exercises (in shares)		64,570
Unrecognized share-based compensation expense, weighted average remaining vesting period		2 years 4 months 24 days	3 years 1 month 6 days
Stock options | Vesting on 1st year anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%	25.00%
Stock options | Vesting ratably 90 days after grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			90 days
Stock options | Vesting ratably over the remaining three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years	3 years
Vesting percentage		75.00%	75.00%
Stock options | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)		1,255,959	571,774
Options granted in period, weighted average grant date fair value (in dollars per share)		$ 4.466	$ 3.350
Stock options | Employee | Vesting on 1st year anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)			446,221
Stock options | Employee | Vesting ratably 90 days after grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)			125,553
Stock options | Non-employee consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)		358,724	1,792,236
Options granted in period, weighted average grant date fair value (in dollars per share)		$ 3.885	$ 0.714
Issuance of shares of Common Stock in connection with stock option exercises (in shares)		64,570
Intrinsic value		$ 0
Stock options | Non-employee consultant | Vesting immediately upon grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
Number of options granted (in shares)			64,570
Stock options | Non-employee consultant | Vesting on 1st year anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		10.00%
Number of options granted (in shares)			1,727,666
Stock options | Non-employee consultant | Vest based on certain performance milestones
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		65.00%

Share-based compensation - Shar

Share-based compensation - Share-based compensation expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	$ 2,302,607	$ 1,760,806
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	1,899,471	398,139
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	$ 403,136	$ 1,362,667

Share-based compensation - Assu

Share-based compensation - Assumptions used in Black-Scholes-Merton option-pricing model (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		65.00%
Expected dividend yield	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.66%	0.11%
Expected term (in years)	4 years 3 months	4 months 6 days
Expected volatility	65.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.16%	0.50%
Expected term (in years)	5 years 4 months 17 days	4 years 3 months
Expected volatility	73.00%

Share-based compensation - Summ

Share-based compensation - Summarizes activity relating to options to purchase stock (Details)	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020$ / sharesshares	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Exchange ratio			3.59
Stock options
Number of Shares (#)
Outstanding as of December 31, 2020 (in shares) | shares	2,364,010
Granted (in shares) | shares	1,614,683	2,364,010
Exercised (in shares) | shares	(64,570)
Forfeited (in shares) | shares	(88,372)
Outstanding as of December 31, 2021(in shares) | shares	3,825,751	2,364,010
Weighted Average Exercise Price ($)
Outstanding as of December 31, 2020 (in dollars per share) | $ / shares	$ 2.88
Granted (in dollars per share) | $ / shares	7.81
Exercised (in dollars per share) | $ / shares	6.97
Forfeited (in dollars per share) | $ / shares	7.80
Outstanding as of December 31, 2021 (in dollars per share) | $ / shares	$ 4.78	$ 2.88
Weighted- Average Remaining Contractual Term (in years)
Outstanding as of December 31, 2021 (in years)	5 years 2 months 12 days
Outstanding at the end of period (in dollars) | $	$ 7,302,047
Vested and expected to vest as of December 31, 2021 (in shares) | shares	3,825,751
Options exercisable as of December 31, 2021 (in shares) | shares	1,018,775
Vested and expected to vest as of December 31, 2021 (in dollars per share) | $ / shares	$ 4.78
Options exercisable as of December 31, 2021 (in dollars per share) | $ / shares	$ 4.60
Vested and expected to vest as of December 31, 2021 (in years)	5 years 2 months 12 days
Options exercisable as of December 31, 2021 (in years)	6 years
Vested and expected to vest (in dollars) | $	$ 7,302,047
Options exercisable as of December 31, 2021 (in dollars) | $	$ 1,825,490

Commitments and contingencies -

Commitments and contingencies - Property in development commitment (Details) - Property, in development commitment - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Other Commitments [Line Items]
Future payments relating to the construction and retrofit of the building	$ 5.6
Total aggregate remaining minimum commitment	$ 6.1	$ 4.9

Commitments and contingencies_2

Commitments and contingencies - Clinical trial and commercial commitments & License agreements (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2021CAD ($)	Dec. 31, 2020USD ($)
Supply agreements in connection with clinical trials
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment	$ 6,800,000
Supply agreements in connection with clinical trials | Minimum
Long-term Purchase Commitment [Line Items]
Minimum purchase commitments	$ 3,800,000
Term for total aggregate remaining minimum commitment	3 years	3 years
Supply agreements in connection with clinical trials | Maximum
Long-term Purchase Commitment [Line Items]
Term for total aggregate remaining minimum commitment	8 years	8 years
Supply agreements in connection | Research and development
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment	$ 3,600,000		$ 100,000
Supply agreement to purchase certain products
Long-term Purchase Commitment [Line Items]
Minimum purchase commitments	49,800,000	$ 62.9
Agreement in connection
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment	0		0
Agreement in connection with the SPLASH clinical phase study
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment	46,400,000
Agreement in connection with the SPLASH clinical phase study | Research and development
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment	$ 8,900,000		$ 1,100,000
Agreement in connection with the SPLASH clinical phase study | Minimum
Long-term Purchase Commitment [Line Items]
Term for total aggregate remaining minimum commitment	1 year	1 year
Agreement in connection with the SPLASH clinical phase study | Maximum
Long-term Purchase Commitment [Line Items]
Term for total aggregate remaining minimum commitment	6 years	6 years

License agreements - License ag

License agreements - License agreement with Scintomics GMBH (Details) - License agreement - Scintomics GMBH ("SCI")	1 Months Ended		12 Months Ended
	Nov. 30, 2019USD ($)	Nov. 30, 2019EUR (€)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Nov. 30, 2019EUR (€)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold prior notice period to terminate the agreement	5 months	5 months
Termination fee	$ 1,400,000	€ 1,250,000
Specified development milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate milestone payments	$ 26,800,000				€ 23,500,000
Research and development | Specified development milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments made			$ 0	$ 1,520,000

License agreements - Research a

License agreements - Research and license agreements with Bach Sciences LLC (Details) - Bach Sciences LLC ("BACH") - USD ($)	1 Months Ended		12 Months Ended
	Jan. 31, 2021	Apr. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Sublicense and collaboration agreement, one
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Option exercise fee		$ 3,250,000	$ 3,250,000
Sublicense and collaboration agreement, one | Research and development
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Option exercise fee				$ 600,000
Payments made			1,250,000	$ 750,000
Sublicense and collaboration agreement, one | Specified development and regulatory milestones | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate milestone payments		8,000,000
Sublicense and collaboration agreement, one | Specified sales milestones | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate milestone payments		$ 38,000,000
Sublicense and collaboration agreement, two
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront fee paid	$ 200,000
Reduction in royalty percentage				100.00%
Sublicense and collaboration agreement, two | Research and development
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront fee recognized as expense			$ 800,000	$ 200,000
Sublicense and collaboration agreement, two | Specified development and regulatory milestones | Maximum | First product developed
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate milestone payments				3,000,000
Sublicense and collaboration agreement, two | Specified development and regulatory milestones | Maximum | Subsequent products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate milestone payments				1,000,000
Sublicense and collaboration agreement, two | Specified sales milestones | Maximum | First product developed
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate milestone payments				45,000,000
Sublicense and collaboration agreement, two | Specified sales milestones | Maximum | Subsequent products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate milestone payments				$ 45,000,000

License agreements - License _2

License agreements - License agreement with Avacta Lifesciences Limited (Details) - License agreement - Avacta Lifesciences Limited ("AVACTA") - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront fee paid	$ 1,000,000
Reduction in royalty percentage	50.00%
Research and development
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront fee recognized as expense	$ 750,000	$ 250,000
Specified regulatory milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate milestone payments	5,000,000
First product developed | Specified development milestones | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate milestone payments	4,500,000
Subsequent products | Specified development milestones | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate milestone payments	$ 3,000,000

License agreements - License _3

License agreements - License agreement with Canadian Molecular Probe Consortium (Details) - License agreement - Canadian Molecular Probe Consortium ("CanProbe")	1 Months Ended		12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2020CAD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020CAD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront fee paid	$ 386,000	$ 500,000
Payments made	$ 188,000	$ 250,000
Reduction in royalty percentage	50.00%	50.00%
Research and development
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront fee recognized as expense			$ 0	$ 574,000
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate milestone payments	$ 2,573,000			$ 2,573,000	$ 3,250,000

License agreements - License _4

License agreements - License agreement with Belgian Nuclear Research Centre (Details) - Jun. 30, 2021 - Belgian Nuclear Research Centre (“SCK-CEN”) - License agreement	USD ($)	EUR (€)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate milestone payments	$ 125,000	€ 110,000
Aggregate minimum royalty payments	$ 8,100,000	7,120,000
Term of agreement	8 years
Aggregate minimum royalty payments		€ 6,300,000

Income taxes - Loss before prov

Income taxes - Loss before provision for income taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U.S.	$ 46,225,053	$ 13,591,329
Canada	(628,230)	(306,208)
Loss before provision for income taxes	$ 45,596,823	$ 13,285,121

Income taxes - Provision for in

Income taxes - Provision for income taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current income tax:
Federal	$ 75	$ 10,000
State	(114)	4,114
Foreign	240,105	73,768
Total current expense	240,066	87,882
Deferred income tax:
Federal	0	0
State	0	0
Foreign	65,592	0
Total deferred expense	65,592	0
Total provision for income tax	$ 305,658	$ 87,882

Income taxes - Reconciliation o

Income taxes - Reconciliation of the United States federal statutory income tax rate to the Company's effective income tax rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Provision for income taxes at the Company’s statutory tax rate of 21%	$ (9,575,333)	$ (2,789,875)
State income taxes, net of federal tax benefit	(1,496,432)	(574,046)
Change in valuation allowance	10,570,870	3,412,396
Permanent items and other	806,553	39,407
Total provision for income tax	$ 305,658	$ 87,882
Statutory tax rate	21.00%	21.00%

Income taxes - Net deferred tax

Income taxes - Net deferred tax assets (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 12,909,104	$ 1,910,665
License agreements	1,763,889	967,268
Start-up costs	233,205	13,679
Share based compensation	811,236	422,280
Reserves and accruals	266,480	45,110
Other	74,763	55,889
Total deferred tax assets	16,058,677	3,414,891
Valuation allowance	(16,054,274)	(3,414,891)
Net deferred tax assets	4,403	0
Unrealized exchange gain	(69,995)	0
Total deferred tax liabilities	(69,995)	0
Net deferred tax liabilities	$ (65,592)	$ 0

Income taxes - Narrative (Detai

Income taxes - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Tax Credit Carryforward [Line Items]
Uncertain tax positions	$ 0	$ 0
Accrued interest and penalties related to income tax	0
Income tax penalties and interest expense related to income tax	0
Domestic Tax Authority
Tax Credit Carryforward [Line Items]
Federal and state net operating loss carryforwards	53,000,000
U.S. net operating loss carryforwards carried forward indefinitely	53,000,000
State and Local Jurisdiction
Tax Credit Carryforward [Line Items]
Federal and state net operating loss carryforwards	41,900,000
Indiana Hoosier Business Tax Credits
Tax Credit Carryforward [Line Items]
Tax credit carryforward	$ 100,000

Net loss per share - Summary of

Net loss per share - Summary of basic and diluted net loss per share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Net loss attributable to common stockholders	$ 45,902,481	$ 13,373,003
Weighted-average common shares outstanding - basic (in shares)	73,850,822	38,875,643
Weighted-average common shares outstanding - diluted (in shares)	73,850,822	38,875,643
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ 0.62	$ 0.34
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ 0.62	$ 0.34

Net loss per share - Anti-dilut

Net loss per share - Anti-dilutive effect (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the computation of diluted net loss per ordinary share (in shares)	3,825,751	5,233,809
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the computation of diluted net loss per ordinary share (in shares)	3,825,751	2,364,010
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the computation of diluted net loss per ordinary share (in shares)	0	2,869,799

Financial instruments risk ma_2

Financial instruments risk management (Details) - USD ($)	Jul. 10, 2020	Dec. 31, 2021	Dec. 31, 2020
Risks and Uncertainties [Abstract]
Foreign currency loss		$ 73,153	$ 164,962
Interest rate	2.85%
LIBOR floor	0.25%

Related party transactions - Sc

Related party transactions - Schedule of Related Party Transactions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Related party expenses	$ 308,989	$ 1,386,878
Share-based compensation for consulting arrangement
Related Party Transaction [Line Items]
Related party expenses	0	1,109,776
Consulting fees to stockholder
Related Party Transaction [Line Items]
Related party expenses	0	164,812
Consulting fees on business activities to Board member
Related Party Transaction [Line Items]
Related party expenses	235,095	90,975
Reimbursement to Board member for occupancy costs
Related Party Transaction [Line Items]
Related party expenses	$ 73,894	$ 21,315

Related party transactions -Nar

Related party transactions -Narrative (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Related Party Transaction [Line Items]
Rent expense with related party	$ 6,000
Share-based compensation for consulting arrangement
Related Party Transaction [Line Items]
Amount due to related party	0
Consulting fees on business activities to Board member
Related Party Transaction [Line Items]
Amount due to related party	73,000
Consulting fees to stockholder
Related Party Transaction [Line Items]
Amount due to related party	$ 0

Employee benefit plan (Details)

Employee benefit plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Percentage of employer matched contribution	50.00%
Percentage of employer matched contribution of eligible employee's compensation	4.00%
Contribution expenses	$ 45,715	$ 2,787

Subsequent events (Details)

Subsequent events (Details) - shares	Jan. 01, 2022	Jan. 01, 2021	Dec. 31, 2021
Subsequent Event [Line Items]
Annual increase in shares authorized, percentage			4.00%
Number of additional shares authorized for issuance under plan (in shares)		3,604,871
Subsequent Event
Subsequent Event [Line Items]
Number of additional shares authorized for issuance under plan (in shares)	3,604,871